Primary Biliary Cholangitis

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

By MedXY 10/28/2025

This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in biochemical responders.

Gastroenterology news Pathology & Lab Medicine

Liver Stiffness Measurement vs. Biochemical Response in Primary Biliary Cholangitis: Predicting Liver Decompensation with Precision

By MedXY 10/28/2025

In primary biliary cholangitis, liver stiffness measurement (LSM) outperforms biochemical response in predicting first hepatic decompensation, emphasizing LSM's pivotal role in clinical risk stratification despite frequent discordances between these parameters.

Gastroenterology news Specialties

The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment

By MedXY 09/21/2025

Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.